Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.43 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7282542 | 0.87 | SIGMAR1 (0.58) | ALDH1A1MEN1KMT2AMAPTSIGMAR1 | |
| SCHEMBL209154 | 0.82 | DRD4 (0.61) | ALDH1A1KMT2AKDM4ESIGMAR1SMN1; SMN2 | |
| SCHEMBL4559554 | 0.80 | DRD4 (0.43) | ALDH1A1KMT2ASIGMAR1DRD4CACNA2D1 | |
| SCHEMBL4558907 | 0.80 | ALDH1A1 (0.50) | ALDH1A1TSHRMEN1KMT2AGLA | |
| SCHEMBL6893683 | 0.76 | ALDH1A1 (0.51) | ALDH1A1MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL4559922 | 0.76 | CACNA2D1 (0.42) | ALDH1A1SIGMAR1POLBDRD4CACNA2D1 | |
| SCHEMBL9099124 | 0.76 | KDM4E (0.42) | ALDH1A1MEN1KMT2AKDM4ESIGMAR1 | |
| SCHEMBL7343072 | 0.75 | CACNA2D1 (0.53) | ALDH1A1TSHRKMT2ASIGMAR1POLB | |
| SCHEMBL4039571 | 0.74 | KMT2A (0.64) | ALDH1A1MEN1KMT2ASIGMAR1SMN1; SMN2 | |
| SCHEMBL10694181 | 0.73 | OPRM1 (0.54) | ALDH1A1KDM4ESIGMAR1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501407-B2 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-6916804-B2 | Pyrimidine A2b selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2005-07-12 | — | — | US | disclosed |
| US-20050119271-A1 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119271-A1 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | ADORA2B, ADORA2A, ADORA3 | ALDH1A1 2146/4885TSHR 68/4885MEN1 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.